What are the clinical presentation and treatment options for Granulomatosis with Polyangiitis (GPA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clinical Presentation of Granulomatosis with Polyangiitis (GPA)

Granulomatosis with polyangiitis (GPA) is characterized by inflammation of small to medium-sized blood vessels with typical features including nasal crusting, stuffiness, epistaxis, scleritis, upper respiratory tract involvement, and often kidney disease when accompanied by active urinary sediment. 1

Key Clinical Manifestations

Upper Respiratory Tract and ENT Involvement

  • Nasal crusting, stuffiness, and epistaxis (nosebleeds) are common presenting symptoms 1
  • Chronic rhinosinusitis with possible nasal polyps 1
  • Otitis media and hearing loss may occur 1
  • Nasal septal perforation can develop in advanced cases 1
  • Scleritis and other ocular manifestations 1

Pulmonary Manifestations

  • Pulmonary infiltrates and nodules are common 1
  • Alveolar hemorrhage can occur in severe cases 1, 2
  • Dyspnea and pleuritic chest pain may be presenting symptoms 2
  • Decreased breath sounds and dullness to percussion at affected lung areas 2

Renal Involvement

  • Glomerulonephritis is a hallmark feature, though not always present at initial presentation 1, 2
  • May manifest as proteinuria, hematuria, and varying degrees of kidney failure 1
  • Rapidly progressive glomerulonephritis with extensive crescent formation in severe cases 3

Other Systemic Manifestations

  • Fever, fatigue, and weight loss are common constitutional symptoms 2
  • Peripheral neuropathy may occur 1
  • Skin lesions including palpable purpura 1
  • Arthralgia and myalgia 1

Laboratory Findings

ANCA Testing

  • Anti-neutrophil cytoplasmic antibodies (ANCA) testing should be performed in all suspected cases 1
  • PR3-ANCA (c-ANCA) is highly specific to GPA and present in 80-90% of cases 1, 4
  • ANCA positivity is not essential for diagnosis but has high diagnostic value 4, 5

Other Laboratory Tests

  • Leukocytosis is common 2
  • Elevated inflammatory markers (ESR, CRP) 4
  • Urinalysis may show hematuria and proteinuria in cases with renal involvement 1

Diagnostic Evaluation

Imaging Studies

  • Chest CT may show consolidation, nodules, or cavitary lesions 2
  • Sinus CT can reveal mucosal thickening, bony destruction, or masses in the nasal cavity and sinuses 2

Histopathology

  • Biopsy of affected organs is paramount for definitive diagnosis 2
  • Characteristic findings include:
    • Necrotizing granulomatous inflammation 4, 2
    • Necrotizing vasculitis of small to medium-sized vessels 4
    • Necrotizing glomerulonephritis in renal specimens 4

Disease Classification and Assessment

  • The Birmingham Vasculitis Activity Score (BVAS) is the primary validated tool for assessing disease activity 6
  • The Five-Factor Score (FFS) predicts mortality risk 6
  • BVAS/WG evaluates manifestations across multiple systems including systemic, cutaneous, mucous/ocular, ENT, pulmonary, cardiovascular, gastrointestinal, and renal 6

Treatment Approach

Induction Therapy

  • Initial therapy includes glucocorticoids combined with either rituximab or cyclophosphamide 1, 7
  • For severe disease with organ-threatening manifestations, combination therapy is essential 7, 3
  • Plasma exchange may be considered in cases with pulmonary hemorrhage or severe renal involvement 1, 3

Maintenance Therapy

  • Options include azathioprine, methotrexate, rituximab, or co-trimoxazole 1
  • Rituximab maintenance has shown efficacy in reducing relapses 5

Prognosis and Monitoring

  • Without treatment, GPA has high mortality rates 5
  • With appropriate treatment, remission can be achieved in more than 80% of cases 5
  • Relapses occur in more than 50% of cases despite treatment 5
  • Regular monitoring of ANCA levels is recommended, though decisions should not be based solely on ANCA titers 6
  • Monitoring for treatment-related complications is essential 7

Common Pitfalls in Diagnosis

  • GPA can mimic infectious diseases, particularly lung abscess or chronic sinusitis, leading to delayed diagnosis 2
  • Initial screening with ANCA serology is recommended in patients with suggestive clinical findings 2
  • Multisystem involvement may not be apparent at initial presentation, requiring high clinical suspicion 2
  • Negative ANCA does not rule out the diagnosis, especially in limited forms of the disease 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Granulomatosis with Polyangiitis: A Case of Nasal Mass, Necrotic Lung, and Normal Kidneys.

Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, 2015

Guideline

Evaluación y Manejo de la Granulomatosis con Poliangiitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.